Frontiers in Immunology (Jul 2017)

Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9–Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA

  • Helena Pulido-Olmo,
  • Helena Pulido-Olmo,
  • Elena Rodríguez-Sánchez,
  • José Alberto Navarro-García,
  • María G. Barderas,
  • Gloria Álvarez-Llamas,
  • Julián Segura,
  • Marisol Fernández-Alfonso,
  • Luis M. Ruilope,
  • Luis M. Ruilope,
  • Luis M. Ruilope,
  • Gema Ruiz-Hurtado

DOI
https://doi.org/10.3389/fimmu.2017.00853
Journal volume & issue
Vol. 8

Abstract

Read online

The protocol describes a novel, rapid, and no-wash one-step immunoassay for highly sensitive and direct detection of the complexes between matrix metalloproteinases (MMPs) and their tissue inhibitor of metalloproteinases (TIMPs) based on AlphaLISA® technology. We describe two procedures: (i) one approach is used to analyze MMP-9–TIMP-1 interactions using recombinant human MMP-9 with its corresponding recombinant human TIMP-1 inhibitor and (ii) the second approach is used to analyze native or endogenous MMP-9–TIMP-1 protein interactions in samples of human plasma. Evaluating native MMP-9–TIMP-1 complexes using this approach avoids the use of indirect calculations of the MMP-9/TIMP-1 ratio for which independent MMP-9 and TIMP-1 quantifications by two conventional ELISAs are needed. The MMP-9–TIMP-1 AlphaLISA® assay is quick, highly simplified, and cost-effective and can be completed in less than 3 h. Moreover, the assay has great potential for use in basic and preclinical research as it allows direct determination of native MMP-9–TIMP-1 complexes in circulating blood as biofluid.

Keywords